$BDSI at breakout $10.00 a triple corrected now

$BDSI at breakout $10.00
a triple corrected now with a triple top.


Website

After hours Pr 6/6/14
BioDelivery Sciences Receives FDA Approval for BUNAVAIL™
(buprenorphine and naloxone) Buccal Film for the Maintenance
Treatment of Opioid Dependence
First and Only FDA-Approved Buccal Film Formulation of Buprenorphine
and Naloxone to Compete in the $1.7 Billion and Growing U.S. Opioid
Dependence Market
Late Third Quarter 2014 Launch Anticipated, Utilizing Dedicated Sales Force
Launch Plans to Be Discussed in Late Summer Investor Briefing
news release


10-Q 3/31/14
O/S shares 48,458,361


recent trades
Stockwatch

Nasdaq
BioDelivery Sciences Receives FDA Approval for BUNAVAIL™
(buprenorphine and naloxone) Buccal Film for the Maintenance
Treatment of Opioid Dependence
6/6/2014 5:19:00 PM - PR Newswire
The IBB Likely To Move Higher Along With These Biotechs With
Catalysts Upcoming
6/2/2014 8:30:00 AM - Seeking Alpha
Orexigen Will Run: Here's Why
5/27/2014 3:47:00 PM - Seeking Alpha
2nd Half Of 2014 Biotechnology Catalysts: Part 1
5/27/2014 9:34:00 AM - Seeking Alpha
Technical Coverage on Top Gainers -- Research on Noranda
Aluminum Holding, Teekay Tankers, BioDelivery Sciences Intl.
and Quality Systems
5/27/2014 6:00:00 AM - PR Newswire


Consensus


% Buy Opinion (composite)

Featured stocks: Coffee Shoppe
For conservative debate: "Keeping it Real"
Game Changing stock $SHMP